Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...

Novo Nordisk scored a much-needed win on Friday, with early-stage data on a new weight-loss drug that suggested it could work better than the obesity blockbusters already on the market. Novo American ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...

Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical development planned.

Just because Wall Street likes a stock doesn't mean it's a great pick. However, it's not a bad idea to at least consider how ...

Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental Big changes are coming to Medicare’s prescription drug coverage (known as Part D) in 2025 that could impact how you pay ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

Intel Corporation (INTC) shares surged 9.3% on takeover speculation following its CEO's December departure. Novo Nordisk A/S (NVO) shares fell 5.3% after Medicare included semaglutide, the key ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...